

# IMPLEMENTATION OF CORRECTIVE ACTION PLANS

Karen Lowney

*Senior Director, Global Compliance  
Cephalon*

Elizabeth A. Lewis

*Vice President, Deputy General Counsel  
Millennium Pharmaceuticals, the Takeda Oncology Company*

Wendy C. Goldstein (Moderator)

*Shareholder  
Epstein Becker & Green, P.C.*

OCTOBER 2008

---

# DISCLAIMER

The Statements Made By the Panelists during this Session Represent His/Her Individual Views and Should Not Be Construed to Represent those of his/her organization.

---



## Audience Polling Question

Fill in the Blank:

In your opinion, \_\_\_\_\_ is the biggest challenge when implementing a corrective action plan approved as part of the resolution of an investigation.



## Audience Polling Question

In your opinion, \_\_\_\_\_ of the CAPs that are approved as part of the resolutions of investigations are completed in their entirety.

1. All
2. More than 75%
3. Between 50% - 75%
4. Less than 50%



## Audience Polling Question

In your opinion, who should be responsible for ensuring that the CAP approved as part of the resolution of an investigation is completed?

1. Compliance department
2. Legal department
3. Human Resources
4. Business



## Audience Polling Question

True or False:

There are never attorney-client privilege considerations when implementing a CAP.

1. True
2. False



## Audience Polling Question

In your opinion, in which location(s) should records relating to the implementation and completion of the CAP be maintained?

1. Compliance department
2. Legal department
3. Human Resources
4. Business
5. Other

# IMPLEMENTATION OF CORRECTIVE ACTION PLANS

Karen Lowney

*Senior Director, Global Compliance  
Cephalon*

Elizabeth A. Lewis

*Vice President, Deputy General Counsel  
Millennium Pharmaceuticals, the Takeda Oncology Company*

Wendy C. Goldstein (Moderator)

*Shareholder  
Epstein Becker & Green, P.C.*

OCTOBER 2008